Strategic Partnerships Orsini has a track record of expanding through exclusive and multi-party collaborations with biopharma and therapy developers, including recent partnerships with Denali Therapeutics, Glaukos, Immedica, and Dos Rx. Sales opportunities exist in co-developing access programs, integrated care pathways, and specialty distribution for high-need, rare-disease therapies.

Expanded Care Delivery With nationwide nursing coverage, in-home infusion services, and integrated 3PL capabilities, Orsini can be positioned as the end-to-end solution for complex therapies requiring hands-on administration, patient adherence programs, and logistics support across multiple geographies.

Orbits of Growth Recent ORBIT Track initiative signals a tech-enabled approach to partner connectivity and data sharing; opportunities exist to implement joint data analytics, outcome capture, and payer-focused value demonstrations to accelerate therapy adoption and market access.

Rare Disease Focus Orsini specializes in rare diseases and gene therapies, with a broad treatment catalog and accreditations, suggesting a strong stance for partnerships with manufacturers seeking specialized distribution, patient support, and regulatory-compliant care models for high-cost, low-volume therapies.

Market Positioning As a leading independent specialty pharmacy with substantial revenue and a sleep of growth through collaborations, Orsini presents as a preferred channel for manufacturers aiming to differentiate via high-touch patient engagement, adherence programs, and comprehensive therapy-specific care teams.